With a population nearing 146 crore, India’s health-care system faces challenges unmatched in scale and complexity. The year 2025 laid bare the system’s underlying fragility — not through a single crisis, but through a convergence of pressures: resurging infectious diseases, a growing non-communicable disease burden, antimicrobial resistance, air pollution, pharmaceutical safety failures, and chronic underfunding. Together, these stresses have underscored an urgent truth: India’s health priorities need realignment, not incremental adjustment.
A Funding Shock That Exposed Vulnerability
One of the most destabilising events of 2025 came from outside India. The United States’ withdrawal from the World Health Organization and subsequent cuts to global health assistance abruptly reduced funding for key programmes in India. Support for HIV/AIDS, maternal and child health, and population services — long backed by PEPFAR and USAID — declined sharply.
Although India is no longer aid-dependent, the sudden funding gap revealed how international assistance had been quietly embedded into critical public health programmes. Union and State governments were forced to reallocate funds at short notice, often without prior budgetary planning, exposing the lack of financial buffers in health governance.
Persistent Underinvestment in Public Health
This external shock was magnified by India’s long-standing underinvestment in health. Public health expenditure remains below 2% of GDP, far short of the National Health Policy target of 2.5%. The Union Budget for 2025–26 allocated just under ₹1 lakh crore to health — an increase in nominal terms, but insufficient relative to population growth, inflation, and rising disease burdens.
While post-pandemic investments expanded diagnostic capacity and hospital infrastructure, funding has not kept pace with epidemiological transition. India is now battling infectious diseases and lifestyle-related illnesses simultaneously, stretching an already overburdened system.
The Quiet Return of Infectious Diseases
Inadequate funding has tangible consequences. Several infectious diseases have shown signs of resurgence, testing surveillance networks, laboratories and frontline workers. The challenge is no longer merely outbreak containment, but reducing preventable deaths and long-term disability — outcomes that require sustained, predictable investment rather than emergency responses.
These pressures coexist with a heavy non-communicable disease load, increasing demand for long-term care, medicines and specialised personnel.
Air Pollution as a Health Emergency
Air pollution has emerged as one of India’s most severe public health threats. Seasonal smog, particularly in northern India, has become a recurring health emergency, aggravating respiratory and cardiovascular conditions. Children, the elderly and those with pre-existing illnesses bear the brunt.
Unlike episodic disease outbreaks, pollution exerts a slow but cumulative toll. Without aggressive, coordinated action — comparable to China’s multi-sectoral interventions — deterioration is likely to continue. Air quality is no longer an environmental issue alone; it is a central determinant of population health.
Tuberculosis: Ambition Outpacing Capacity
India’s failure to meet its self-imposed goal of eliminating tuberculosis by 2025 highlights the limits of ambition without adequate capacity. Advances such as molecular diagnostics and newer drug regimens have improved detection and treatment. Indigenous tools like TrueNat have strengthened early diagnosis.
Yet multidrug-resistant TB continues to rise, and detection rates vary widely across States. Weak follow-up systems, workforce shortages and uneven funding have prevented sustained progress. TB elimination remains possible, but not without deeper investment and systemic strengthening.
Antimicrobial Resistance: A Looming Crisis
Antimicrobial resistance (AMR) represents perhaps the most dangerous long-term threat. WHO data indicates that one in three bacterial infections in India involves resistant organisms — double the global average. Resistance levels are especially high in intensive care units.
Unregulated antibiotic sales, self-medication, incomplete treatment, pharmaceutical pollution and weak enforcement drive this crisis. Kerala’s success in reducing community-level resistance through stewardship programmes shows that policy can work — but replication requires political commitment and resources.
Pharmaceutical Safety and Erosion of Trust
The most disturbing failure of 2025 was the death of children from contaminated cough syrup containing diethylene glycol. Coming after earlier international scandals, this tragedy exposed deep regulatory lapses.
For a country aspiring to be the “pharmacy of the world”, repeated quality failures undermine global credibility and domestic trust. Regulation, inspection and accountability must match manufacturing scale — otherwise growth becomes a liability rather than a strength.
Why Health Reform Cannot Wait
India’s health challenges are deeply interconnected. Underfunding weakens surveillance; pollution amplifies chronic disease; poor regulation endangers patients; and antimicrobial resistance threatens to undo decades of medical progress.
As 2026 approaches, marginal increases and isolated fixes will not suffice. India needs a decisive shift: higher public health spending, stronger pharmaceutical oversight, tighter antibiotic stewardship, and coordinated action on air quality.
Conclusion
The promise of “health for all” remains within reach, but only if health is treated as a core national investment rather than a discretionary expense. A healthy population is not merely a social objective — it is the foundation of economic growth, resilience and national security. The lessons of 2025 are clear: delay will only raise the cost of reform, in lives as well as livelihoods.
Month: Current Affairs - Dec 30, 2025
Category: